Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

March 17, 2006 at 2:29 PM

Nosing up again

After Nastech Pharmaceutical lost a big-name partner at the beginning of the month, analysts at Needham & Co., dropped their rating on the stock.

Since then, the Bothell company has generated enough positive news to convince the analysts to restore their “buy” rating Friday. Investors followed suit, trading the stock up $1.64, 10.4 percent, to close at $17.41.

This week, Nastech marched out a new partnership with Novo Nordisk, promising early results of its RNA interference therapy candidates against flu and fourth-quarter and full-year results slightly ahead of analyst expectations.

Nastech is developing drugs formulated for nasal delivery to treat obesity, osteoporosis and other indications.

Comments | More in Biotechnology

COMMENTS

No personal attacks or insults, no hate speech, no profanity. Please keep the conversation civil and help us moderate this thread by reporting any abuse. See our Commenting FAQ.



The opinions expressed in reader comments are those of the author only, and do not reflect the opinions of The Seattle Times.


The Seattle Times

The door is closed, but it's not locked.

Take a minute to subscribe and continue to enjoy The Seattle Times for as little as 99 cents a week.

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Subscriber login ►
The Seattle Times

To keep reading, you need a subscription upgrade.

We hope you have enjoyed your complimentary access. For unlimited seattletimes.com access, please upgrade your digital subscription.

Call customer service at 1.800.542.0820 for assistance with your upgrade or questions about your subscriber status.

The Seattle Times

To keep reading, you need a subscription.

We hope you have enjoyed your complimentary access. Subscribe now for unlimited access!

Subscription options ►

Already a subscriber?

We've got good news for you. Unlimited seattletimes.com content access is included with most subscriptions.

Activate Subscriber Account ►